Frontage Holdings (01521) Surges Nearly 50% on Trading Resumption; Tigermed Participates in Privatization and Divests Overseas Laboratory Business

Stock News11-10

Frontage Holdings (01521) surged nearly 50% upon trading resumption, rising 39.6% to HK$2.08 as of press time, with a turnover of HK$12.5288 million.

On the news front, Tigermed announced that the company intends to sell its controlling stake in its subsidiary Frontage Holdings and divest its overseas laboratory business. The transaction consists of two parts: a privatization and a spin-off transaction.

The company's wholly-owned subsidiary Hong Kong Tigermed, together with CRL, Dr. Li Song, and others, jointly established SanRex as the acquisition vehicle to privatize Frontage Holdings by way of a scheme of arrangement. Upon completion of the privatization, Frontage Holdings will become a wholly-owned subsidiary of SanRex.

After the spin-off transaction is completed, the company will no longer hold any shares in Frontage Holdings and will only retain the non-target business within China. In the spin-off transaction, the initial transaction prices for the target business, the non-target business outside China, and the non-target business within China are US$470 million, US$84.4 million, and US$205.5 million, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment